Nothing said here yet.
to join the conversation.
| Seshadri VishwasChief Executive Officer | Sell | 19,608 | $101.1K | Tue, Sep 29 |
| Vazzano Joseph WalterChief Financial Officer | Sell | 9,191 | $47.4K | Tue, Sep 29 |
| O'Malley Brendan M.SVP, Chief Legal Officer | Sell | 6,727 | $34.7K | Tue, Sep 29 |
| Vasanthavada MadhavChief Commercial Officer | Sell | 4,902 | $25.3K | Tue, Sep 29 |
| Alvino MarkDirector | Sell | 15,000 | $88.0K | Tue, Sep 1 |
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.
Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference.
Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc.
CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company.
On August 13, Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter results that captured a company scaling a genuinely new kind of medicine while working through the bumps that come with it.
Despite manufacturing hiccups and patient cancellations, the company expands its treatment center network and secures CMS NTAP status to bolster market access.
By David Bautz, PhD NASDAQ: ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Five Patients Treated in 2Q26; 12 Patients Treated in Total Thus Far Abeona Therapeutics, Inc (NASDAQ: ABEO) is continuing the commercial launch of Zevaskyn®, with five…